Nesrina Imami

List of Publications by Year
in descending order

75 papers	1,852 citations	279798 23 h-index	276875 41 g-index
77 all docs	77 docs citations	77 times ranked	2378 citing authors

#	Article	IF	Citations
1	Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4+ T cell decline and increased immune activation during acute infection. PLoS Pathogens, 2020, 16, e1008853.	4.7	8
2	Pregnancy Gestation Impacts on HIV-1-Specific Granzyme B Response and Central Memory CD4 T Cells. Frontiers in Immunology, 2020, 11, 153.	4.8	3
3	Title is missing!. , 2020, 16, e1008853.		0
4	Title is missing!. , 2020, 16, e1008853.		0
5	Title is missing!. , 2020, 16, e1008853.		0
6	Title is missing!. , 2020, 16, e1008853.		0
7	Pregnancy-related immune suppression leads to altered influenza vaccine recall responses. Clinical Immunology, 2019, 208, 108254.	3.2	8
8	Progesterone-Related Immune Modulation of Pregnancy and Labor. Frontiers in Endocrinology, 2019, 10, 198.	3.5	133
9	Short Communication: Therapeutic Immunization Benefits Mucosal-Associated Invariant T Cell Recovery in Contrast to Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, and Recombinant Human Growth Hormone Addition in HIV-1+ Treated Patients: Individual Case Reports from Phase I Trial. AIDS Research and Human Retroviruses, 2019, 35, 306-309.	1.1	6
10	Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP). Blood, 2019, 134, 2364-2364.	1.4	1
11	Progesterone Modulation of Pregnancy-Related Immune Responses. Frontiers in Immunology, 2018, 9, 1293.	4.8	60
12	Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. OncoImmunology, 2017, 6, e1304337.	4.6	15
13	Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune Activation. Frontiers in Immunology, 2017, 8, 1138.	4.8	64
14	Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 Controllers. Frontiers in Immunology, 2017, 8, 746.	4.8	4
15	A stepwise advance out of the shadows: leading HIV to its clearance. Future Virology, 2015, 10, 1263-1266.	1.8	0
16	Multifarious immunotherapeutic approaches to cure HIV-1 infection. Human Vaccines and Immunotherapeutics, 2015, 11, 2287-2293.	3.3	5
17	Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. Vaccine, 2014, 32, 7005-7013.	3.8	14
18	Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. Frontiers in Immunology, 2013, 4, 58.	4.8	19

#	Article	IF	Citations
19	African ancestry and innate immunity contribute to the incidence of multicentric Castlemanâ€™s disease in HIV-1/Kaposiâ€™s sarcoma herpesvirus-coinfected individuals. Future Virology, 2012, 7, 729-734.	1.8	4
20	CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection. Molecular Medicine, 2012, 18, 1240-1248.	4.4	21
21	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. Journal of Immunological Methods, 2012, 375, 46-56.	1.4	11
22	Are Long-Term Non-Progressors Very Slow Progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988â€“2010. PLoS ONE, 2012, 7, e29844.	2.5	30
23	T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness. Aids, 2011, 25, 1981-1986.	2.2	3
24	T-cell dysfunction in HIV-1 infection: targeting the inhibitors. HIV Therapy, 2010, 4, 83-99.	0.6	4
25	Transient Nature of Long-Term Nonprogression and Broad Virus-Specific Proliferative T-Cell Responses with Sustained Thymic Output in HIV-1 Controllers. PLoS ONE, 2009, 4, e5474.	2.5	22
26	Novel approach to recognition of predicted HIV-1 Gag BâŽ3501-restricted CD8 T-cell epitopes by HLA-BâŽ3501+ patients: Confirmation by quantitative ELISpot analyses and characterisation using multimers. Journal of Immunological Methods, 2009, 341, 76-85.	1.4	10
27	Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. Journal of Immune Based Therapies and Vaccines, 2008, 6, 7.	2.4	19
28	Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. Vaccine, 2008, 26, 5107-5110.	3.8	5
29	Toll-like Receptor 4 Mediates Innate Immunity to Kaposi Sarcoma Herpesvirus. Cell Host and Microbe, 2008, 4, 470-483.	11.0	98
30	Recent HIV-1 infection in a high-risk Ugandan cohort: implications for Phase IIB test-of-concept HIV vaccine trials. Pharmacogenomics, 2007, 8, 409-414.	1.3	4
31	Old Rhesus Macaques Treated with Interleukin-7 Show Increased TREC Levels And Respond Well to Influenza Vaccination. Rejuvenation Research, 2007, 10, 5-18.	1.8	78
32	Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy. Future HIV Therapy, 2007, 1, 171-179.	0.4	7
33	Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. Aids, 2007, 21, 375-377.	2.2	9
34	Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. Aids, 2007, 21, 1379-1381.	2.2	27
35	A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. Journal of Immune Based Therapies and Vaccines, 2007, 5, 6.	2.4	21
36	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. Antiviral Therapy, 2007, 12, 553-558.	1.0	6

#	Article	IF	Citations
37	An anniversary without celebration?. Nature Immunology, 2006, 7, 893-893.	14.5	0
38	Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: Concomitant assessment of perforin, IFN-Î³ and IL-4 secretion. Journal of Immunological Methods, 2006, 308, 216-230.	1.4	12
39	A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2. Aids, 2006, 20, 1564-1565.	2.2	1
40	Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. Aids, 2005, 19, 1761-1769.	2.2	81
41	The importance of standardisation of laboratory evaluations in HIV vaccine trials. Microbes and Infection, 2005, 7, 1424-32.	1.9	9
42	Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. Journal of Leukocyte Biology, 2005, 78, 37-42.	3.3	21
43	CCR2/64I mutation detection in a HIV-1-positive patient with slow CD4 T-cell decline and delay in disease progression. International Journal of STD and AIDS, 2005, 16, 392-395.	1.1	6
44	HIV Type 1-Specific Inter- and Intrasubtype Cellular Immune Responses in HIV Type 1-Infected Ugandans. AIDS Research and Human Retroviruses, 2004, 20, 763-771.	1.1	8
45	Distinct Patterns of Peripheral HIVâ€1â€“Specific Interferonâ€Î³ Responses in Exposed HIVâ€1â€“Seronegative Individuals. Journal of Infectious Diseases, 2004, 189, 1705-1713.	4.0	34
46	HIV Type 1 Antigen-Responsive CD4+T-Lymphocytes in Exposed Yet HIV Type 1 Seronegative Ugandans. AIDS Research and Human Retroviruses, 2004, 20, 67-75.	1.1	23
47	The challenge of developing an effective HIV-1 vaccine. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 461-467.	0.5	1
48	Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses. Aids, 2004, 18, 2199-2202.	2.2	9
49	Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 783-790.	2.1	32
50	Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. Antiviral Therapy, 2004, 9, 67-75.	1.0	11
51	Enhanced T-Cell Maturation, Differentiation and Function in HIV-1-Infected Individuals after Growth Hormone and Highly Active Antiretroviral Therapy. Antiviral Therapy, 2004, 9, 67-75.	1.0	25
52	Twenty years of HIV-1 research: what the future holds. Nature Immunology, 2003, 4, 501-501.	14.5	1
53	Kaposi's Sarcoma-Associated Herpesvirus Cytotoxic T Lymphocytes Recognize and Target Darwinian Positively Selected Autologous K1 Epitopes. Journal of Virology, 2003, 77, 4306-4314.	3.4	45
54	Thymic Output during Initial Highly Active Antiretroviral Therapy (HAART) and during HAART Supplementation with Interleukin 2 and/or with HIV Type 1 Immunogen (Remune). AIDS Research and Human Retroviruses, 2003, 19, 103-109.	1.1	31

#	Article	IF	Citations
55	Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. Aids, 2003, 17, 1411-1413.	2.2	29
56	Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. Aids, 2003, 17, 628-629.	2.2	13
57	Timing of antiretroviral therapy: an immunological perspective. Journal of HIV Therapy, 2003, 8, 15-8.	0.6	1
58	A Balanced Type 1/Type 2 Response Is Associated with Long-Term Nonprogressive Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2002, 76, 9011-9023.	3.4	91
59	Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. Aids, 2002, 16, 531-536.	2.2	76
60	Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy. Journal of Virology, 2002, 76, 2634-2640.	3.4	91
61	Molecular quantitation of thymic output in mice and the effect of IL-7. European Journal of Immunology, 2002, 32, 2827-2836.	2.9	55
62	Immune reconstitution in HIV-1-infected patients. Current Opinion in Investigational Drugs, 2002, 3, 1138-45.	2.3	5
63	Mechanisms of loss of HIV-1-specific T-cell responses. Journal of HIV Therapy, 2002, 7, 30-4.	0.6	3
64	Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Immunology Letters, 2001, 79, 63-76.	2.5	32
65	The Exon A (C77G) Mutation Is a Common Cause of Abnormal CD45 Splicing in Humans. Journal of Immunology, 2001, 166, 6144-6148.	0.8	21
66	Development of immunotherapeutic strategies for HIV-1. Expert Opinion on Biological Therapy, 2001, 1, 803-816.	3.1	13
67	A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. Aids, 2001, 15, 1892-1894.	2.2	44
68	Loss of CD4+T Cell Proliferative Ability but Not Loss of Human Immunodeficiency Virus Type 1 Specificity Equates with Progression to Disease. Journal of Infectious Diseases, 2000, 182, 792-798.	4.0	126
69	Assessment of Type 1 and Type 2 Cytokines in HIV Type 1-Infected Individuals: Impact of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 1999, 15, 1499-1508.	1.1	85
70	Therapeutic vaccines in HIV. 1 infection. Immunological Reviews, 1999, 170, 173-182.	6.0	19
71	The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family. European Journal of Immunology, 1998, 28, 4071-4083.	2.9	31
72	K21-Antigen: A Molecule Shared by the Microenvironments of the Human Thymus and Germinal Centers. Autoimmunity, 1998, 6, 41-52.	0.6	2

#	Article	IF	Citations
73	ASSOCIATION BETWEEN INTERLEUKIN-4-PRODUCING T LYMPHOCYTE FREQUENCIES AND REDUCED RISK OF GRAFT-VERSUS-HOST DISEASE1. Transplantation, 1998, 65, 979-988.	1.0	24
74	Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4-producing human T cells. International Immunology, 1994, 6, 1575-1584.	4.0	22
75	Interleukin-21 Receptor Expression on CD8 T Cells: A Potential Biomarker of HIV-1 Disease State and Trajectory. SSRN Electronic Journal, 0, , .	0.4	0